Description: Neuren Pharmaceuticals Limited (Neuren) is a biopharmaceutical company engaged in developing drugs for neurological disorders. The Company develops therapies for brain injury, neurodevelopmental and neurodegenerative disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. Its products include NNZ-2566 and NNZ-2591. Its lead product, NNZ-2566 (Trofinetide), is in Phase II trial for the treatment of Rett syndrome, Fragile X syndrome, moderate to severe Traumatic Brain Injury (TBI) and Concussion. Trofinetide is an analog of a molecule, which is derived from insulin-like growth factor-1 (IGF-1) and occurs naturally in the brain. Its NNZ-2591 product is in Pre-clinical and Phase I trial for the treatment of other neurological conditions. Its subsidiaries include Hamilton Pharmaceuticals Inc. and Neuren Pharmaceuticals Inc.
Home Page: www.neurenpharma.com
NEU Technical Analysis
697 Burke Road
Camberwell,
VIC
3124
Australia
Phone:
61 3 9092 0480
Officers
| Name | Title |
|---|---|
| Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons) | CEO, MD & Director |
| Ms. Lauren Frazer C.A. | CFO & Company Sec. |
| Mr. Lawrence Glass | Chief Science Officer |
| Mr. Gerry Zhao | VP of Corp. Devel. |
| Dr. Liza A. Squires M.D. | Chief Medical Officer |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 21.1864 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 27.4534 |
| Price-to-Sales TTM: | 298.5137 |
| IPO Date: | 2005-02-03 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |